Thierry Dervieux

List of Publications by Year
in descending order

46 papers	2,519 citations	236612 25 h-index	233125 45 g-index
46 all docs	46 docs citations	46 times ranked	2469 citing authors

#	Article	IF	Citations
1	Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 2766-2774.	6.7	312
2	Pharmacogenetics and cancer therapy. Nature Reviews Cancer, 2001, 1, 99-108.	12.8	227
3	Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clinical Chemistry, 1998, 44, 551-555.	1.5	193
4	Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 3095-3103.	6.7	188
5	Contribution of common polymorphisms in reduced folate carrier and ??-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics and Genomics, 2004, 14, 733-739.	5.7	155
6	Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 607-612.	6.7	148
7	Liquid Chromatography–Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine Therapy. Clinical Chemistry, 2005, 51, 2074-2084.	1.5	105
8	Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics and Genomics, 2002, 12, 605-611.	5.7	92
9	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100, 1240-1247.	0.6	87
10	HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis. Clinical Chemistry, 2003, 49, 1632-1641.	1.5	87
11	Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology, 2010, 49, 2337-2345.	0.9	71
12	Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 334-341.	1.4	69
13	Measurement of cell–bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 4040-4047.	6.7	66
14	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science and Medicine, 2014, 1, e000056.	1.1	65
15	Gene–gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenetics and Genomics, 2009, 19, 935-944.	0.7	51
16	Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 573, 180-194.	0.4	47
17	Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography–mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clinical Chemistry, 1998, 44, 2511-2515.	1.5	42
18	Cell-bound complement activation products in SLE. Lupus Science and Medicine, 2017, 4, e000236.	1.1	39

#	Article	IF	Citations
19	Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenetics and Genomics, 2012, 22, 1-9.	0.7	38
20	Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. Future Science OA, 2015, 1, FSO26.	0.9	35
21	Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Science and Medicine, 2019, 6, e000318.	1.1	34
22	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatologyâ€"Classified Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 78-88.	2.9	33
23	Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics, 2006, 7, 1175-1184.	0.6	32
24	Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. Annals of the Rheumatic Diseases, 2014, 73, e36-e36.	0.5	27
25	Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 908-910.	0.5	25
26	Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Science and Medicine, 2016, 3, e000127.	1.1	24
27	Phenotype Determination of Thiopurine Methyltransferase in Erythrocytes by HPLC. Clinical Chemistry, 2001, 47, 956-958.	1.5	23
28	High-performance liquid chromotographic determination of methyl 6-mercaptopurine nucleotides (Me6-MPN) in red blood cells: analysis of Me6-MPN per se or Me6-MPN derivative?. Biomedical Applications, 1999, 730, 273-274.	1.7	19
29	Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 434-436.	0.5	19
30	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine, 2016, 3, e000165.	1.1	18
31	Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. Journal of Immunological Methods, 2017, 446, 54-59.	0.6	18
32	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine, 2018, 5, e000263.	1.1	18
33	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clinical Chemistry, 2002, 48, 61-8.	1.5	16
34	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics, 2003, 73, 506-516.	2.3	14
35	Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases. journal of applied laboratory medicine, The, 2019, 4, 40-49.	0.6	13
36	Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. Rheumatology, 2009, 48, 597-598.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Detection of anti-dsDNA antibodies by computer-aided automated immunofluorescence analysis. Journal of Immunological Methods, 2016, 433, 17-22.	0.6	10
38	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Science and Medicine, 2019, 6, e000349.	1.1	9
39	Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus. Clinical Immunology, 2021, 228, 108755.	1.4	9
40	Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. Journal of Immunology Research, 2017, 2017, 1-5.	0.9	8
41	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	1.1	7
42	Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not. Clinical and Experimental Rheumatology, 2013, 31, 433-5.	0.4	7
43	Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Annals of the Rheumatic Diseases, 2019, 78, 1285-1286.	0.5	5
44	Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: Comment on the article by Stamp et al. Arthritis and Rheumatism, 2010, 62, 2559-2560.	6.7	2
45	Diagnostic performance of a new anti-carbamylated protein assay in rheumatic diseases. Scandinavian Journal of Rheumatology, 2019, 48, 249-250.	0.6	1
46	Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability: reply. Rheumatology, 2009, 48, 1620-1620.	0.9	0